The absorption of human calcitonin from the transverse colon of man

被引:17
作者
Antonin, KH
Rak, R
Bieck, PR
Preiss, R
Schenker, U
Hastewell, J
Fox, R
Mackay, M
机构
[1] CIBA PHARMACEUT,CNS RES,CH-4002 BASEL,SWITZERLAND
[2] CIBA GEIGY GMBH,INST HUMAN PHARMACOL,D-72072 TUBINGEN,GERMANY
[3] UNIV LEIPZIG,INST CLIN PHARMACOL,D-04107 LEIPZIG,GERMANY
[4] UNIV LEIPZIG,DEPT SURG,D-04107 LEIPZIG,GERMANY
[5] CIBA GEIGY PHARMACEUT CORP,DRUG DISCOVERY,HORSHAM RH12 4AB,W SUSSEX,ENGLAND
[6] CIBA GEIGY PHARMACEUT CORP,ECE,HORSHAM RH12 4AB,W SUSSEX,ENGLAND
关键词
human calcitonin; absorption; oral drug delivery; loop stoma; colon; human study;
D O I
10.1016/0378-5173(95)04248-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Patients with a loop stoma were used to provide direct access to the transverse colon. The ease of delivery offers the chance to study absorption of human calcitonin (hCT) in a defined region of the large intestine difficult to access in healthy volunteers; i.v. infused hCT elicited a standard pharmacokinetic profile in eight loop stoma patients showing a biphasic elimination with half-lives of 11.5 +/- 0.8 min and 33.7 +/- 1.8 min. hCT administration via the loop stoma was absorbed across the transverse colonic mucosa in low amounts. The 10-mg dose achieved a mean maximum plasma concentration of 1242 +/- 346 pg ml(-1), after 5-10 min with an absolute bioavailability of 0.22 +/- 0.06%. We conclude that the transverse colon is a better site for the absorption of human calcitonin than the more distal regions of the colon. This could be a function of the transverse colonic epithelium. Alternatively, it could be due to the reduced levels of luminal debris and bacterial colonisation in the stoma patients compared with the previous studies carried out in the distal colon of healthy volunteers.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 17 条
[1]   COLONIC ABSORPTION OF HUMAN CALCITONIN IN MAN [J].
ANTONIN, KH ;
SAANO, V ;
BIECK, P ;
HASTEWELL, J ;
FOX, R ;
LOWE, P ;
MACKAY, M .
CLINICAL SCIENCE, 1992, 83 (05) :627-631
[2]   CALCITONIN - PHYSIOLOGY AND PATHO-PHYSIOLOGY [J].
AUSTIN, LA ;
HEATH, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (05) :269-278
[3]   INTRACOLONIC BIOAVAILABILITY OF HUMAN CALCITONIN IN MAN [J].
BEGLINGER, C ;
BORN, W ;
MUFF, R ;
DREWE, J ;
DREYFUSS, JL ;
BOCK, A ;
MACKAY, M ;
FISCHER, JA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (05) :527-531
[4]  
CUMMINGS J H, 1990, Gastroenterology, V98, pA408
[5]  
GENNARI C, 1983, LANCET, P594
[6]   TREATMENT OF PAGETS-DISEASE OF BONE WITH SYNTHETIC HUMAN CALCITONIN - BIOCHEMICAL AND ROENTGENOLOGIC CHANGES [J].
GREENBERG, PB ;
DOYLE, FH ;
FISHER, MT ;
HILLYARD, CJ ;
JOPLIN, GF ;
PENNOCK, J ;
MACINTYRE, I .
AMERICAN JOURNAL OF MEDICINE, 1974, 56 (06) :867-870
[7]   ABSORPTION OF HUMAN CALCITONIN ACROSS THE RAT COLON INVIVO [J].
HASTEWELL, J ;
LYNCH, S ;
WILLIAMSON, I ;
FOX, R ;
MACKAY, M .
CLINICAL SCIENCE, 1992, 82 (05) :589-594
[8]   ENHANCEMENT OF HUMAN CALCITONIN ABSORPTION ACROSS THE RAT COLON IN-VIVO [J].
HASTEWELL, J ;
LYNCH, S ;
FOX, R ;
WILLIAMSON, I ;
SKELTONSTROUD, P ;
MACKAY, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 101 (1-2) :115-120
[9]  
MACKAY M, 1991, BIOTECHNOL GENET ENG, V8, P251
[10]  
MACKAY M, 1993, COLONIC DRUG ABSORPT, P159